BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30219698)

  • 21. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
    Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
    Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Ibatici A; Browne P; Czerw T; Socie G; Unal A; Kyrcz-Krzemien S; Bacigalupo A; Goker H; Potter M; Furness CL; McQuaker G; Beelen D; Milpied N; Campos A; Craddock C; Nagler A; Mohty M
    Oncologist; 2016 Mar; 21(3):377-83. PubMed ID: 26869584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.
    Bejanyan N; Weisdorf DJ; Logan BR; Wang HL; Devine SM; de Lima M; Bunjes DW; Zhang MJ
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):454-9. PubMed ID: 25460355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic cell transplantation in non-Hodgkin's lymphomas.
    Aldoss I; Nademanee A
    Cancer Treat Res; 2015; 165():329-44. PubMed ID: 25655617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
    McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.
    Selberg L; Stadtherr P; Dietrich S; Tran TH; Luft T; Hegenbart U; Bondong A; Meissner J; Liebers N; Schmitt M; Ho AD; Müller-Tidow C; Dreger P
    Bone Marrow Transplant; 2021 Jan; 56(1):30-37. PubMed ID: 32555407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Giebel S; Boumendil A; Labopin M; Seesaghur A; Baron F; Ciceri F; Esteve J; Gorin NC; Savani B; Schmid C; Wetten S; Mohty M; Nagler A
    Ann Hematol; 2019 Oct; 98(10):2389-2398. PubMed ID: 31392462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
    Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
    Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.
    Naik S; Martinez CA; Omer B; Sasa G; Yassine K; Allen CE; Kamdar K; Orth R; Wu M; Leung K; Gottschalk S; Brenner MK; Heslop HE; Krance RA
    Blood Adv; 2019 Sep; 3(18):2689-2695. PubMed ID: 31511228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers.
    van Kempen-Harteveld ML; Brand R; Kal HB; Verdonck LF; Hofman P; Schattenberg AV; van der Maazen RW; Cornelissen JJ; Eijkenboom WM; van der Lelie JP; Oldenburger F; Barge RM; van Biezen A; Vossen JM; Noordijk EM; Struikmans H
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1444-54. PubMed ID: 18294781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
    Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
    Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
    Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
    Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.